Quarterly report pursuant to sections 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v2.4.0.8
Commitments and Contingencies - Additional Information (Detail) (USD $)
 1 Months Ended 9 Months Ended
Dec. 31, 2013
Feb. 28, 2014
Project
Commitment And Contingencies [Line Items]    
Cash severance payment   $ 234,400
Option immediate vesting   50,000
Asset Purchase Agreement Aggregate Consideration Paying Period   10 years
Progenics Pharmaceuticals, Inc
    
Commitment And Contingencies [Line Items]    
Royalty on every net sales   5.00%
Initial Payment
    
Commitment And Contingencies [Line Items]    
Asset purchase, cash paid   3,500,000
Milestone Payments | US Phase III trial
    
Commitment And Contingencies [Line Items]    
Asset purchase, cash paid   1,500,000
Milestone Payments | US new drug application approval by the FDA
    
Commitment And Contingencies [Line Items]    
Asset purchase, cash paid   5,000,000
Development Milestone Payments
    
Commitment And Contingencies [Line Items]    
Royalty on every net sales   7.50%
Asset Purchase Agreement Aggregate Consideration Paying Period   10 years
Minimum annual license maintenance fees   150,000
Development Milestone Payments | US Phase III trial
    
Commitment And Contingencies [Line Items]    
Asset purchase, cash paid   1,000,000
Development Milestone Payments | US new drug application approval by the FDA
    
Commitment And Contingencies [Line Items]    
Asset purchase, cash paid   500,000
Development Milestone Payments | New Drug Application with the FDA
    
Commitment And Contingencies [Line Items]    
Asset purchase, cash paid   500,000
Project Work Order
    
Commitment And Contingencies [Line Items]    
Number of research studies projects   2
Estimated combined cost of the studies   9,300,000
Termination period upon prior notice   30 days
Percentage of remaining contract amount for direct services to be paid upon termination   30.00%
Payment to CRO for deposit 790,000  
Postponed research studies amounts allowed to be applied to all amounts due to the CRO   343,000
Project Work Order | Amarex Clinical Research, LLC
    
Commitment And Contingencies [Line Items]    
Estimated combined cost of the studies   5,100,000
Director
    
Commitment And Contingencies [Line Items]    
Salary   13,890
Cash severance payment   $ 13,890
Severance period   33 months
Reimbursement of health insurance period   9 months
Director | Stock Option Award Agreement dated Dec 6,2010
    
Commitment And Contingencies [Line Items]    
Stock option award agreement   500,000
Stock Option granted   $ 1.19
Director | Stock Option Award Agreement dated September 22,2010
    
Commitment And Contingencies [Line Items]    
Options granted   25,000
Director | Stock Option Award Agreement dated April 16,2012
    
Commitment And Contingencies [Line Items]    
Stock option award agreement   750,000
Stock Option granted   $ 2.00
Option immediate vesting   1,500,000
Options forfeiture   750,000